WO1994025069A1 - Transdermale wirkstoffzubereitung - Google Patents
Transdermale wirkstoffzubereitung Download PDFInfo
- Publication number
- WO1994025069A1 WO1994025069A1 PCT/EP1994/001259 EP9401259W WO9425069A1 WO 1994025069 A1 WO1994025069 A1 WO 1994025069A1 EP 9401259 W EP9401259 W EP 9401259W WO 9425069 A1 WO9425069 A1 WO 9425069A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- active ingredient
- preparation according
- tocopherol
- skin
- diclofenac
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Definitions
- transdermal administration of active substances is appropriate in cases in which a high local concentration d active substances in the tissue under the intact skin is required, while the oral or parenteral systemic administration leads to undesirable systemic side effects or does not result in this type of administration can provide the required local concentration.
- Active ingredients such as heparin sodium are generally used in high concentrations because of their low skin permeability. The intestinal absorption of this drug is negligible. Systemic effects are undesirable in peripheral injuries. Many topical active ingredient formulations can sensitize, dry out or even damage the skin where it is applied.
- Water-containing creams or ointments which are often intended to avoid some of these undesirable side effects, must contain microbiological preservatives, which in turn often lead to skin sensitization. There is therefore a need for safe, non-irritating and additionally skin-protecting absorption accelerators, which are active ingredients with a low level Skin permeability are beneficial to the
- Diclofenac sodium is an example of an extraordinarily frequently used non-steroidal anti-inflammatory active ingredient (NSAID), with regard to its problem-free and well-established clinical effectiveness.
- NSAID non-steroidal anti-inflammatory active ingredient
- topical forms of administration for regional rheumatic complaints are desired for chronic use.
- metabolism in the first passage after oral administration which occurs in the liver and leads to partial inactivation, can be avoided by topical administration.
- diclofenac was chosen as an example of active ingredients with low skin permeability.
- topical diclofenac sodium preparations strongly depends on the ability of the preparation to allow the active ingredient to penetrate the intact skin.
- the cornea represents a barrier to any active substance permeation of the skin and the penetration into the underlying inflamed tissue.
- D The permeability of intact skin for diclofenac sodium is low, various attempts have been made to increase the skin permeation by using different salts.
- IL-A-62 160 describes diclofenac amine salts for increased skin penetration.
- This salt is more lipophilic than the sodium salt and can permeate the skin at a higher rate.
- the use of this salt is not without risk.
- Secondary amines are known to form highly carcinogenic nitrosamines.
- the preparation additionally contains diethylamine as a neutralizing agent for acrylic acid, which acts as a gel-forming agent for the gel preparation. Since secondary amines have these potential side effects, the German authorities responsible for registration recommended that these amines be used in cosmetic and pharmaceutical preparations to replace.
- EP-A-0 372 527 describes the use of a hydroxyethylpyrrolidine salt of diclofenac with a higher water solubility than the sodium salt.
- This salt has been combined with various absorption promoters, for example ethoxylated glycerides, lanolin esters or lecithin. Only in conjunction with these new salts were the absorption promoters able to accelerate absorption to the extent that the diethylamine salt. Compare Clin. Tri. J., 26 (1989) 304-309 (Galzigna et al.: Percutaneous adsorption of diclofenac after topical application, Two different gel formulations). JP-A-02.049 722 describes the use of ammonia as a neutralizing agent for polyacrylic acid gels containing diclofenac sodium.
- EP-A-0 498 011 describes rubidium or cesium salts of diclofenac with a higher skin permeation in vitro than with the sodium salt.
- the use of these salts is critical, however, since both ions have their own pharmacological effects. Antidepressant effects occur in this way, and cesium in particular increases the cerebral concentrations of serotonin and tryptophan. Its very long elimination half-time (50 to 100 days) can lead to an accumulation in the body after chronic administration. Rubidium also shows a long elimination half-time (40 days) and leads to long-term accumulation.
- EP-A-0 245 126 describes the calcium salt of diclofenac in combination with toxicologically risky absorption promoters, such as DMSO and azone.
- toxicologically risky absorption promoters such as DMSO and azone.
- various preparations containing synthetic absorption promoters have been developed.
- JP-A-01.013 020 describes diclofenac sodium emulsions for topical use which contain dialkyl carboxylates and fatty acids. A protective agent must also be added to reduce the microbiological contamination.
- heterocyclic penetrations accelerators such as imidazolines or oxazolines, are used for topical pharmaceuticals from Diclofenac.
- US-A-4 670 254 describes diclofenac sodium gels which contain a high amount of ethanol and propylene glycol.
- Ethanol is a known absorption promoter for various active substances.
- Ethanol and propylene glycol are solvents for lipids and have the disadvantage that they dry out the skin.
- JP-A-60.146 823 uses nicotinates as absorption accelerators. As active ingredients, they lead to increased circulation and increased blood flow and thus accelerate the transport from the application site. They lead to heat sensations and annoying side effects.
- EP-A-0 147 476 uses glycols and salicylates or peppermint oil or menthol as absorption accelerators, but these substances can cause skin irritation and peppermint oil or menthol can cause a burning sensation or skin sensitization.
- the permeability can advantageously be improved by the addition of vitamin E ( ⁇ -tocopherol) or by the addition of vitamin E derivatives.
- the combination of phospholipids with tocopherol or tocopherol derivatives and short-chain aliphatic alcohols leads to an unexpectedly high skin permeation with active ingredients with low permeation rates.
- active substances are non-steroidal anti-inflammatory, antithrombotic, analgesic, anesthetic, antibiotic, hormonal and ant allergic substances.
- the active substance preparations can be topical solutions, foams, sprays, gels, pastes, ointments, emulsions and liposomal dispersions. Since antimicrobial activity is present at low alcohol concentrations, the use of additional preservatives is not necessary. Since tocopherol or a tocopherol derivative is provided according to the invention, no further antioxidant guarantee is required.
- Active substance preparations of the composition according to the invention are safe, non-toxic, well tolerated and show a skin protection effect which is due to tocopherol or tocopherol derivatives. It is important to focus on the cosmetic preparations used on a large scale, which are intended to prevent exogenous skin damage, for example due to UV radiation.
- the preparations according to the invention are superior in comparison with known topical active substance preparations, since adsorption promoter or possibly non-dangerous salts can be avoided which can lead to skin irritation or even skin damage
- Diethylammoniumdiclofenac gel showed a permeation of about 2000 ug of active ingredient / 2, 5 cm 2/24 hr. Comparative Example 2 (Diclofenac Sodium)
- Table 1 Amounts of diclofenac sodium ( ⁇ g / 2.5 cm 2 ) diffused in 24 h in various solvents
- PL phospholipid (as indicated above)
- Table 2 Amounts of diclofenac sodium ( ⁇ g / 2.5 cm 2 ) diffused in 24 h after adding PL, ⁇ -tocopherol or ⁇ -tocopherol acetate and IPA.
- Both preparations contained identical amounts of PL and IPA.
- the solution contained 5% d, 1- ⁇ -tocopherol acetate and the gel 1% d- ⁇ -tocopherol.
- the gel also contained 1.5% polyacrylic acid and a sufficient amount of triethanolamine to gel the polymer.
- a mixture of synthetic oil components was incorporated into the gel. The data of skin permeation in vitro of a complete diclofenac Na gel preparation can be seen in FIG. 2.
- the following gel can be used as a topical antithrombotic preparation:
- the following gel can be spread very well on the skin. It can be applied to inflamed areas of the body.
- Application example 3 was repeated (application example 4) of the 1 percent.
- Diclofenac Na gel was applied to the backs of 12 test subjects in each case 7.5 g and washed off after 6 hours of application.
- FIG. 3 shows that in application example 4 the plasma level still rose when the applications were terminated. In contrast, in comparative application example 1, the plasma level already fell before the application was terminated with an application duration of about 5 hours. This drop should be attributed to the fact that the comparison gel has no phospholipid and / or ⁇ -tocopherol content.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU67210/94A AU6721094A (en) | 1993-04-23 | 1994-04-22 | Transdermal active-substance preparation |
JP52384794A JP4334613B2 (ja) | 1993-04-23 | 1994-04-22 | 経皮医薬品製剤 |
DK94915529T DK0695193T3 (da) | 1993-04-23 | 1994-04-22 | Transdermale aktivstof-præparater |
EP94915529A EP0695193B1 (de) | 1993-04-23 | 1994-04-22 | Transdermale wirkstoffzubereitung |
US08/535,035 US5738869A (en) | 1993-04-23 | 1994-04-22 | Transdermal drug preparation |
DE59407810T DE59407810D1 (de) | 1993-04-23 | 1994-04-22 | Transdermale wirkstoffzubereitung |
FI954990A FI114444B (fi) | 1993-04-23 | 1995-10-19 | Menetelmä aktiiviainetta sisältävän transdermaalisen valmisteen valmistamiseksi |
NO19954215A NO311919B1 (no) | 1993-04-23 | 1995-10-20 | Transdermalt medikament |
GR990401042T GR3029963T3 (en) | 1993-04-23 | 1999-04-16 | Transdermal active-substance preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4313402A DE4313402A1 (de) | 1993-04-23 | 1993-04-23 | Transdermale Wirkstoffzubereitung |
DEP4313402.5 | 1993-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994025069A1 true WO1994025069A1 (de) | 1994-11-10 |
Family
ID=6486248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1994/001259 WO1994025069A1 (de) | 1993-04-23 | 1994-04-22 | Transdermale wirkstoffzubereitung |
Country Status (13)
Country | Link |
---|---|
US (1) | US5738869A (de) |
EP (1) | EP0695193B1 (de) |
JP (1) | JP4334613B2 (de) |
AT (1) | ATE176593T1 (de) |
AU (1) | AU6721094A (de) |
DE (2) | DE4313402A1 (de) |
DK (1) | DK0695193T3 (de) |
ES (1) | ES2130420T3 (de) |
FI (1) | FI114444B (de) |
GR (1) | GR3029963T3 (de) |
NO (1) | NO311919B1 (de) |
WO (1) | WO1994025069A1 (de) |
ZA (1) | ZA942848B (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19517145C2 (de) * | 1995-05-10 | 2000-02-24 | Hexal Pharmaforschung Gmbh | Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron |
CN1072482C (zh) * | 1996-11-08 | 2001-10-10 | 山东医科大学 | 低分子肝素脂质体喷胶剂及制备工艺 |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6623752B1 (en) * | 1996-07-02 | 2003-09-23 | Hexal Ag | Patch for transdermal application for pergolid |
DE19641259A1 (de) * | 1996-10-07 | 1998-04-16 | Kade Pharma Fab Gmbh | Arzneimittel auf Basis von Diclofenac |
US20010003580A1 (en) * | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
DE19945522A1 (de) * | 1999-09-23 | 2001-04-05 | Hexal Ag | Pharmazeutisches, wirkstoffhaltiges Gel |
BR0001144B1 (pt) * | 2000-02-21 | 2013-10-22 | Composicão farmacêutica de diclofenaco à base de vitamina-e, papaína e hialuronidase | |
DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
DE10066158B4 (de) * | 2000-08-24 | 2007-08-09 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms |
DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
DE10137082A1 (de) * | 2001-07-28 | 2003-02-13 | Hexal Ag | Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol |
US20040224010A1 (en) * | 2002-11-15 | 2004-11-11 | Optime Therapeutics, Inc. | Ophthalmic liposome compositions and uses thereof |
WO2004057950A2 (en) * | 2002-12-20 | 2004-07-15 | Idexx Laboratories, Inc. | Liposomal analgesic formulation and use |
US6936273B2 (en) * | 2002-12-20 | 2005-08-30 | Idexx Laboratories, Inc. | Liposomal analgesic formulation and use |
US8795703B2 (en) | 2004-09-28 | 2014-08-05 | Atrium Medical Corporation | Stand-alone film and methods for making the same |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
ES2613387T3 (es) * | 2005-03-31 | 2017-05-24 | Unilever N.V. | Administración mejorada de agentes de beneficio de la piel |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
EP2626063B1 (de) | 2006-10-17 | 2022-03-16 | Nuvo Pharmaceuticals Inc. | Diclofenac-Gel |
JP5371235B2 (ja) * | 2006-12-06 | 2013-12-18 | ロート製薬株式会社 | 皮膚外用剤 |
WO2009101412A1 (en) * | 2008-02-13 | 2009-08-20 | Cipla Limited | Topical pharmaceutical composition |
US8618164B2 (en) | 2009-03-31 | 2013-12-31 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
PT2387391T (pt) * | 2009-07-24 | 2017-04-20 | Mika Pharma Ges Für Die Entw Und Vermarktung Pharmazeutischer Produkte Mbh | Processo para o desenvolvimento de uma composição líquida a ser aplicada na forma de espuma sobre a pele e composição de aplicação tópica |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
US10322213B2 (en) | 2010-07-16 | 2019-06-18 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
DE102013004199A1 (de) * | 2012-05-15 | 2013-11-21 | Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh | Pharmazeutische Zusammensetzung |
US20130309215A1 (en) * | 2012-05-15 | 2013-11-21 | Mika Pharma Gesellschaft Fur Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh | Pharmaceutical composition |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
JP6449554B2 (ja) * | 2014-03-30 | 2019-01-09 | 小林製薬株式会社 | 外用医薬組成物 |
WO2016109400A2 (en) | 2014-12-31 | 2016-07-07 | Lantheus Medical Imaging, Inc. | Lipid-encapsulated gas microsphere compositions and related methods |
JP6542006B2 (ja) * | 2015-03-31 | 2019-07-10 | 小林製薬株式会社 | 外用医薬組成物 |
BR112018072342A2 (pt) | 2016-05-04 | 2019-02-19 | Lantheus Medical Imaging, Inc. | métodos e dispositivos para preparação de agentes de contraste de ultrassom |
US9789210B1 (en) | 2016-07-06 | 2017-10-17 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
CA3038702A1 (en) * | 2016-10-18 | 2018-04-26 | Lts Lohmann Therapie-Systeme Ag | Two-layer topical therapeutic system |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0343694A2 (de) * | 1984-03-07 | 1989-11-29 | Roshdy Dr. Ismail | Mittel zur Behandlung und zum Schutz der Haut |
EP0372527A1 (de) * | 1988-12-09 | 1990-06-13 | Altergon S.A. | Topisch anzuwendende Diclofenac enthaltende Arzneizubereitungen |
WO1990006736A1 (en) * | 1988-12-16 | 1990-06-28 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
EP0383162A1 (de) * | 1989-02-16 | 1990-08-22 | CASSELLA Aktiengesellschaft | Verwendung einer Wirkstoffkombination zur Behandlung rheumatischer Erkrankungen |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2374910A1 (fr) * | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
US4439432A (en) * | 1982-03-22 | 1984-03-27 | Peat Raymond F | Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols |
FR2548021B1 (fr) * | 1983-06-29 | 1986-02-28 | Dick P R | Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels |
EP0151989B1 (de) * | 1984-01-28 | 1991-04-10 | Roshdy Dr. Ismail | Mittel zur Behandlung von Herzerkrankungen |
DE3402928A1 (de) * | 1984-01-28 | 1985-08-08 | Roshdy Dipl.-Chem. Dr. 5000 Köln Ismail | Mittel zur behandlung von herzerkrankungen |
US4612194A (en) * | 1984-02-15 | 1986-09-16 | Roshdy Ismail | Anti-rheumatic agents and their use |
DE3507791A1 (de) * | 1984-03-07 | 1985-09-26 | Roshdy Ismail | Mittel zum schutz der haut |
DE3446873A1 (de) * | 1984-12-21 | 1986-07-10 | Merckle Gmbh | Fluessige diclofenac-zubereitungen |
DE3506881A1 (de) * | 1985-02-27 | 1986-08-28 | RODISMA pharmazeutische Produkte GmbH, 5000 Köln | Vitamin e spray |
CH666621A5 (de) * | 1986-06-27 | 1988-08-15 | Ciba Geigy Ag | Topisch applizierbare pharmazeutische zusammensetzungen mit systemischer wirkung. |
US4745105A (en) * | 1986-08-20 | 1988-05-17 | Griffin Charles C | Low molecular weight heparin derivatives with improved permeability |
US4745107A (en) * | 1986-08-20 | 1988-05-17 | Foley Kevin M | Heparin derivatives with improved permeability |
DE3908047A1 (de) * | 1989-03-13 | 1990-09-20 | Desitin Arzneimittel Gmbh | Hochdisperse pharmazeutische zusammensetzung |
WO1992016236A1 (en) * | 1991-03-19 | 1992-10-01 | Rajadhyaksha Vithal J | Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers |
US5498420A (en) * | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
-
1993
- 1993-04-23 DE DE4313402A patent/DE4313402A1/de not_active Withdrawn
-
1994
- 1994-04-22 ES ES94915529T patent/ES2130420T3/es not_active Expired - Lifetime
- 1994-04-22 AU AU67210/94A patent/AU6721094A/en not_active Abandoned
- 1994-04-22 WO PCT/EP1994/001259 patent/WO1994025069A1/de active IP Right Grant
- 1994-04-22 US US08/535,035 patent/US5738869A/en not_active Expired - Lifetime
- 1994-04-22 AT AT94915529T patent/ATE176593T1/de active
- 1994-04-22 DE DE59407810T patent/DE59407810D1/de not_active Expired - Lifetime
- 1994-04-22 DK DK94915529T patent/DK0695193T3/da active
- 1994-04-22 EP EP94915529A patent/EP0695193B1/de not_active Expired - Lifetime
- 1994-04-22 JP JP52384794A patent/JP4334613B2/ja not_active Expired - Lifetime
- 1994-04-25 ZA ZA942848A patent/ZA942848B/xx unknown
-
1995
- 1995-10-19 FI FI954990A patent/FI114444B/fi not_active IP Right Cessation
- 1995-10-20 NO NO19954215A patent/NO311919B1/no not_active IP Right Cessation
-
1999
- 1999-04-16 GR GR990401042T patent/GR3029963T3/el unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0343694A2 (de) * | 1984-03-07 | 1989-11-29 | Roshdy Dr. Ismail | Mittel zur Behandlung und zum Schutz der Haut |
EP0372527A1 (de) * | 1988-12-09 | 1990-06-13 | Altergon S.A. | Topisch anzuwendende Diclofenac enthaltende Arzneizubereitungen |
WO1990006736A1 (en) * | 1988-12-16 | 1990-06-28 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
EP0383162A1 (de) * | 1989-02-16 | 1990-08-22 | CASSELLA Aktiengesellschaft | Verwendung einer Wirkstoffkombination zur Behandlung rheumatischer Erkrankungen |
Non-Patent Citations (2)
Title |
---|
J. SZULC ET AL.: "herstellung von liposomen mit den vitaminen a und e", DIE PHARMAZIE, vol. 47, no. 5, May 1992 (1992-05-01), BERLIN (DE), pages 386 - 387, XP000287884 * |
M. MAHJOUR ET AL.: "effect of egg yolk lecithins and commercial soybean lecithins on in vitro skin permeation of drugs", JOURNAL OF CONTROLLED RELEASE, vol. 14, no. 3, December 1990 (1990-12-01), AMSTERDAM (NL), pages 243 - 252, XP000165642 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19517145C2 (de) * | 1995-05-10 | 2000-02-24 | Hexal Pharmaforschung Gmbh | Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron |
CN1072482C (zh) * | 1996-11-08 | 2001-10-10 | 山东医科大学 | 低分子肝素脂质体喷胶剂及制备工艺 |
Also Published As
Publication number | Publication date |
---|---|
AU6721094A (en) | 1994-11-21 |
DK0695193T3 (da) | 1999-09-20 |
NO311919B1 (no) | 2002-02-18 |
FI954990A0 (fi) | 1995-10-19 |
NO954215L (no) | 1995-12-14 |
ATE176593T1 (de) | 1999-02-15 |
EP0695193A1 (de) | 1996-02-07 |
NO954215D0 (no) | 1995-10-20 |
US5738869A (en) | 1998-04-14 |
ZA942848B (en) | 1995-10-25 |
GR3029963T3 (en) | 1999-07-30 |
ES2130420T3 (es) | 1999-07-01 |
FI954990A (fi) | 1995-11-23 |
DE59407810D1 (de) | 1999-03-25 |
JPH08509715A (ja) | 1996-10-15 |
DE4313402A1 (de) | 1994-10-27 |
EP0695193B1 (de) | 1999-02-10 |
FI114444B (fi) | 2004-10-29 |
JP4334613B2 (ja) | 2009-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994025069A1 (de) | Transdermale wirkstoffzubereitung | |
EP1282446B1 (de) | Pharmazeutische und/oder kosmetische zubereitung enthaltend ein organosiloxan und ein phospholipid | |
DE3111767A1 (de) | Mittel zur behandlung der haut | |
DE69724629T2 (de) | Zusammensetzungen und deren verwendungen | |
DD298352A5 (de) | Tretinoin enthaltende zubereitung und verfahren zu ihrer herstellung | |
EP1641459B1 (de) | Verwendung von aus extremophilen bakterien gewonnenen osmolyten zur herstellung von arzneimitteln zur äusserlichen behandlung der neurodermitis | |
US6573302B1 (en) | Cream utilizing capsaicin | |
EP0214620B1 (de) | Transdermale Applikationsform von Diltiazem | |
DE69725575T2 (de) | Verwendung von vitamine e acetat | |
DE2841346A1 (de) | Mittel zur behandlung der haut mit antiviraler wirkung | |
WO2001021148B1 (de) | No-freisetzende topisch applizierbare zusammensetzung als biologisches mittel, deren herstellung und deren verwendung als dermatika und/oder kosmetika | |
DE69828586T2 (de) | Azelastinhydrochlorid-enthaltende perkutane Formulierung mit guter perkutaner Absorptionsfähigkeit und verringerter Hautreizung | |
EP1392243B1 (de) | Pharmazeutische zusammensetzung | |
EP0803254A1 (de) | Acetylsalicylsäure enthaltende alkoholische Lösungen zur perkutanen Anwendung, deren Verwendung zur antithrombotischen Therapie sowie Arzneimittel | |
EP0450123A1 (de) | Diclofenac-Natrium enthaltende pharmazeutische Zusammensetzung zur topischen Anwendung | |
EP2620146A1 (de) | Ibuprofen zur Behandlung von aktinischer Keratose | |
WO2002069927A1 (de) | Melatonin-vitamin-a-präparate | |
AT504040B1 (de) | Diclofenac-hältige zubereitung zur behandlung von verbrennungen | |
EP0620000A2 (de) | Kosmetische und/oder pharmazeutische Verwendung von N-Acylalkanolaminen | |
EP1003499B1 (de) | Zur topischen applikation bestimmte diclofenac-lösung | |
WO1996012504A1 (de) | Topisch anzuwendende öl-in-wasser-formulierung | |
DE19641259A1 (de) | Arzneimittel auf Basis von Diclofenac | |
DE2551962C3 (de) | Verwendung eines Extraktes aus verschiedenen Spezies von Helleborus | |
DE102015115107A1 (de) | Cineolhaltige wässrige Zusammensetzung für die nasale Applikation | |
DE202022001251U1 (de) | Pharmazeutisches Hautpflegemittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 954990 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994915529 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08535035 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1994915529 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994915529 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 954990 Country of ref document: FI |